Latest News for: idiopathic hypersomnia
Edit
Idiopathic Hypersomnia (IH) Market View 2025: Market Awaits Disease-Modifying Options with 11 Molecules in Development ...
Nasdaq Globe Newswire 18 Jun 2025
Explore the evolving competitive landscape in Idiopathic Hypersomnia Therapeutics with our comprehensive data-driven report.
Edit
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZTM (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia (Form 8-K) (Avadel Pharmaceuticals plc)
Public Technologies 05 Jun 2025
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZTM (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia ... Hypersomnia (IH).
- 1